No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
ArriVent BioPharma Advances Cancer Therapeutics Pipeline
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $36
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $38
HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $36 Price Target
ArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy Rating
ArriVent BioPharma GAAP EPS of -$0.61 Beats by $0.11